You are here

Marcel R.M. van den Brink

Marcel VandenBrink
Marcel R.M.
van den Brink
M.D., Ph.D.
Division of Hematologic Oncology Alan N. Houghton Chair
Memorial Sloan-Kettering Cancer Center

Marcel R.M. van den Brink is Head of the Division of Hematologic Oncology and the incumbent of the Alan Houghton Chair in Immunology at Memorial Sloan-Kettering Cancer Center, and Professor in Immunology at Weill Graduate School of Medical Sciences-Cornell University in New York City, USA. He obtained his M.D. and Ph.D. from the University of Leiden, The Netherlands, and carried out a post-doctoral fellowship with Steven J. Burakoff at the Dana Farber Cancer Institute in Boston, MA.  His research is focused on the Immunology of hematopoietic stem cell transplantation.  Dr. van den Brink is an attending physician on the bone marrow transplantation service.

Select Publications: 

Na IK, Lu SX, Yim NL, Goldberg GL, Tsai J, Rao U, Smith OM, King CG, Suh D, Hirschhorn-Cymerman D, Palomba L, Penack O, Holland AM, Jenq RR, Ghosh A, Tran H, Merghoub T, Liu C, Sempowski GD, Ventevogel M, Beauchemin N, van den Brink MR. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest. 2010 Jan;120(1):343-56. doi: 0.1172/JCI39395.

Penack O, Smith OM, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Brandl K, van den Brink MR. NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med. 2009 Sep 28;206(10):2101-10.

Goldberg GL, King CG, Nejat RA, Suh DY, Smith OM, Bretz JC, Samstein RM, Dudakov JA, Chidgey AP, Chen-Kiang S, Boyd RL, van den Brink MR. Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol. 2009 May 1;182(9):5846-54.

Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao UK, Yim NL, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MR. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood. 2009 Feb 12;113(7):1574-80.

Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, Holland AM, Grubin J, Mark NM, Liu C, Iwakura Y, Heller G, van den Brink MR. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009 Jan 22;113(4):945-52.

Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, Gao GJ, Suh D, King C, Chow M, Smith OM, Hubbard VM, Bautista JL, Cabrera-Perez J, Zakrzewski JL, Kochman AA, Chow A, Altan-Bonnet G, van den Brink MR. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood. 2008 Dec 15;112(13):5254-8.

Alpdogan SO, Lu SX, Patel N, McGoldrick S, Suh D, Budak-Alpdogan T, Smith OM, Grubin J, King C, Goldberg GL, Hubbard VM, Kochman AA, van den Brink MR. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation. Blood. 2008 Dec 1;112(12):4755-64.

Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Ziga-Pflcker JC, Lu C, van den Brink MR. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008 Apr;26(4):453-61.

Kim TD, Terwey TH, Zakrzewski JL, Suh D, Kochman AA, Chen ME, King CG, Borsotti C, Grubin J, Smith OM, Heller G, Liu C, Murphy GF, Alpdogan O, van den Brink MR. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood. 2008 Mar 1;111(5):2929-40.

Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. J Immunol. 2007 Aug 1;179(3):1669-80.

Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MR. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood. 2007 Jul 15;110(2):783-6.